PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 9, 2010Journal of Clinical Oncology484 citations

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

View Full Paper
MLMario E. LacoutureEMEdith P. MitchellBPBilal Piperdi

Key Points

Key points are not available for this paper at this time.

Abstract

The pre-emptive skin treatment regimen was well tolerated. The incidence of specific >or= grade 2 skin toxicities during the 6-week skin treatment period was reduced by more than 50% in the pre-emptive group compared with the reactive group. Patients in the pre-emptive group reported less QOL impairment than patients in the reactive group.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lacouture et al. (2010) studied this question.

synapsesocial.com/papers/69d76c03ef4aa71f97f314b8https://doi.org/10.1200/jco.2008.21.7828
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epidermal growth factor-related peptides and their receptors in human malignancies1995 · 2,696 citations
  2. 2Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB)2007 · 17 citations
  3. 3Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use1994 · 5,626 citations
  4. 4Keratinocyte Apoptosis Induced by Ultraviolet B Radiation and CD95 Ligation – Differential Protection through Epidermal Growth Factor Receptor Activation and Bcl-xL Expression2001 · 36 citations
  5. 5Tetracyclines: Nonantibiotic properties and their clinical implications2006 · 776 citations